Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dr Reddy’s Gears For Sputnik Pediatric Shot, Molnupiravir Upside

Executive Summary

Dr Reddy’s indicates it is close to break-even between “the investment made and what we gained” for Russian COVID-19 vaccine Sputnik V in India, with Sputnik Light, boosters and pediatric shots seen as the new growth drivers. The company’s fully vertically integrated operations also puts it in prime position for supplies of antiviral molnupiravir.

You may also be interested in...



The MPP And Merck Partner For Molnupiravir In Lower-Income Countries

The Medicines Patent Pool has signed its first agreement to provide access for a COVID-19 medical technology with Merck & Co, to increase access of generic molnupiravir to 150 lower income countries. 

Merck’s Molnupiravir Open License With Medicines Patent Pool May Be Model

Pharma industry critics herald the agreement for allowing many manufacturers around the world to make the COVID-19 therapeutic and for its transparency. If Merck can do it, they ask, why can’t other companies?

Pediatric COVID-19 Vaccine Face-Off Looms As Bharat Biotech Heads For Approval

While Bharat Biotech is close to an accelerated approval of Covaxin in two to 18-year-olds, Zydus Cadila is yet to roll out its COVID-19 vaccine in India. As they head to a face-off in pediatric vaccines, the former faces manufacturing constraints and the latter hesitance over a first of its kind DNA vaccine. Experts speak to Scrip on which one stands a better chance of winning.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151391

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel